About
Watch to hear the techniques of survival analysis, their application in economic evaluations, and lessons learned from conducting survival analysis on immature data, addressing the challenges of analyzing different outcomes.

Health economic models often rely on estimates of time-to-event for outcomes – e.g. time to disease progression, time to first stroke, time to death – to estimate costs and health outcomes over lifetime. Time-to-event, or “survival”, analysis is used to provide estimates of survivor functions and event rates that inform these models. As well as characterizing event rates over an observed period, such as the duration of a clinical trial, survival analysis techniques are employed to extrapolate over lifetime to generate estimates of mean survival benefit.

Estimates of the cost-effectiveness of an intervention can be sensitive to the methods applied in modeling and extrapolating survival data. Standard parametric models are preferred when the underlying distribution of survival times is well-understood and can be adequately described by a specific parametric form; advanced survival methods are needed for more complex or heterogeneous data.

Key Topics:

  • What is survival analysis and how is it used in economic evaluations

  • Recent applications in the field of survival analysis

  • Lessons learned when conducting survival analysis on immature data

  • Challenges in conducting survival analyses on different outcomes (overall survival, progression-free survival, duration of treatment)

Presenters
1721143687-ab09070ee115f4ff
Tim Baker, BS
Lead Consultant, Health Economics-Epidemiology, ICON
Tim Baker has been working in HEOR research and economic modeling since 2000. With experience in economic model design and implementation in multiple disease areas, he has supported HTA submissions in more than a dozen countries, including integration and leverage of survival extrapolation from trial data.
1721143872-59f5ccdabca4f991
Manikanta Dasari, BPharm, MTech
Lead Consultant, Health Economics-Epidemiology, ICON
With more than ten years of experience in health economics and outcomes research (HEOR), Manikanta Dasari specializes in developing early economic models, global submission models, as well as supporting country specific HTA submissions. His expertise encompasses a wide range of therapeutic areas, with a notable focus on oncology.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Country / Region*
Job Title*
Job Level*
Organization / Company*
What is your experience in using survival analysis for HTA submissions?*
What are your greatest challenges in conducting survival analysis using clinical trial data?*
Immaturity of data
Cross-over
Identifying appropriate distributions
Patient Heterogeneity
Validating extrapolated data
All of the above
Other
utm_bmcr_source
Registration Terms
This event is hosted by HealthEconomics.com (a Scientist.com company). By registering and participating, you acknowledge that your personal data will be processed by HealthEconomics.com. You also agree to receive email communication from HealthEconomics.com about this webinar and other programs of similar nature. The sponsor of this webinar is ICON; by registering and participating, you acknowledge that your data will be processed in accordance with ICON's Privacy Policy. You will receive email communication from ICON about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Yes, I consent to the registration terms.*
Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.